Journal of Clinical Oncology, Vol 7, 803-815, Copyright © 1989 by American Society of Clinical Oncology

ARTICLES

Tamoxifen therapy in primary breast cancer: biology, efficacy, and side effects

RR Love
Department of Human Oncology, University of Wisconsin, Clinical Cancer Center, Madison.

Since its introduction into clinical use in the early 1970s, the synthetic antiestrogen tamoxifen citrate has been shown to contribute to the control of human breast cancer in increasingly significant ways. While its mechanisms of action and pharmacology are incompletely understood, tamoxifen appears to act predominantly by blocking the action of estrogen by binding to the estrogen receptor. Clinical trials of tamoxifen for 1 to 2 years in primary breast cancer demonstrate consistent beneficial effects on disease-free survival, but only suggested beneficial effects on survival. Routine use of adjuvant tamoxifen for 5 years or more will depend on the results of ongoing large clinical trials of efficacy and detailed studies of unknown biological effects on other tissues.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T Yoshimura, T Sumida, S Liu, A Onishi, S Shintani, P-Y Desprez, and H Hamakawa Growth inhibition of human salivary gland tumor cells by introduction of progesterone (Pg) receptor and Pg treatment Endocr. Relat. Cancer, December 1, 2007; 14(4): 1107 - 1116. [Abstract] [Full Text] [PDF]

				A. Zheng, A. Kallio, and P. Harkonen Tamoxifen-Induced Rapid Death of MCF-7 Breast Cancer Cells Is Mediated via Extracellularly Signal-Regulated Kinase Signaling and Can Be Abrogated by Estrogen Endocrinology, June 1, 2007; 148(6): 2764 - 2777. [Abstract] [Full Text] [PDF]

				S. Mabuchi, M. Ohmichi, A. Kimura, Y. Ikebuchi, K. Hisamoto, E. Arimoto-Ishida, Y. Nishio, K. Takahashi, K. Tasaka, and Y. Murata Tamoxifen Inhibits Cell Proliferation via Mitogen-Activated Protein Kinase Cascades in Human Ovarian Cancer Cell Lines in a Manner Not Dependent on the Expression of Estrogen Receptor or the Sensitivity to Cisplatin Endocrinology, March 1, 2004; 145(3): 1302 - 1313. [Abstract] [Full Text] [PDF]

				D. F. Hayes Playing the Old Piano: Another Tune for Endocrine Therapy? J Natl Cancer Inst, November 5, 2003; 95(21): 1565 - 1567. [Full Text] [PDF]

				M. Piccart, L. M. Parker, and K. I. Pritchard Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer Ann. Onc., July 1, 2003; 14(7): 1017 - 1025. [Abstract] [Full Text] [PDF]

				A. H. Partridge, P. S. Wang, E. P. Winer, and J. Avorn Nonadherence to Adjuvant Tamoxifen Therapy in Women With Primary Breast Cancer J. Clin. Oncol., February 15, 2003; 21(4): 602 - 606. [Abstract] [Full Text] [PDF]

				A. H. Partridge, J. Avorn, P. S. Wang, and E. P. Winer Adherence to Therapy With Oral Antineoplastic Agents J Natl Cancer Inst, May 1, 2002; 94(9): 652 - 661. [Abstract] [Full Text] [PDF]

				V. C. L. Lin, A. S. Eng, N. E. Hen, E. H. L. Ng, and S. H. Chowdhury Effect of Progesterone on the Invasive Properties and Tumor Growth of Progesterone Receptor-transfected Breast Cancer Cells MDA-MB-231 Clin. Cancer Res., September 1, 2001; 7(9): 2880 - 2886. [Abstract] [Full Text] [PDF]

				S. Mandlekar, R. Yu, T.-H. Tan, and A.-N. T. Kong Activation of Caspase-3 and c-Jun NH2-terminal Kinase-1 Signaling Pathways in Tamoxifen-induced Apoptosis of Human Breast Cancer Cells Cancer Res., November 1, 2000; 60(21): 5995 - 6000. [Abstract] [Full Text]

				V. C-L. Lin, E. H. Ng, S. E. Aw, M. G-K. Tan, E. H-L. Ng, V. S-W. Chan, and G. H. Ho Progestins Inhibit the Growth of MDA-MB-231 Cells Transfected with Progesterone Receptor Complementary DNA Clin. Cancer Res., February 1, 1999; 5(2): 395 - 403. [Abstract] [Full Text] [PDF]

				J. D. Sibonga, H. Dobnig, R. M. Harden, and R. T. Turner Effect of the High-Affinity Estrogen Receptor Ligand ICI 182,780 on the Rat Tibia Endocrinology, September 1, 1998; 139(9): 3736 - 3742. [Abstract] [Full Text] [PDF]

				P. M. Mannucci, D. Bettega, V. Chantarangkul, A. Tripodi, V. Sacchini, and U. Veronesi Effect of Tamoxifen on Measurements of Hemostasis in Healthy Women Arch Intern Med, September 9, 1996; 156(16): 1806 - 1810. [Abstract] [PDF]

				R. R. Love, T. S. Surawicz, and E. C. Williams Antithrombin III Level, Fibrinogen Level, and Platelet Count Changes With Adjuvant Tamoxifen Therapy Arch Intern Med, February 1, 1992; 152(2): 317 - 320. [Abstract] [PDF]

				R. R. Love, D. A. Wiebe, P. A. Newcomb, L. Cameron, H. Leventhal, V. C. Jordan, J. Feyzi, and D. L. DeMets Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal Women Ann Intern Med, December 1, 1991; 115(11): 860 - 864. [Abstract] [PDF]

				R. R. Love, L. Cameron, B. L. Connell, and H. Leventhal Symptoms Associated With Tamoxifen Treatment in Postmenopausal Women Arch Intern Med, September 1, 1991; 151(9): 1842 - 1847. [Abstract] [PDF]